Direkt zum Inhalt
Merck

Fortfahren mit

42129

Lathosterolamid MGI-39

≥97.0% (HPLC)

Synonym(e):

(3S,20S)-20-N-(2-Methylpropyl)-carbamoylpregn-7-en-3β-ol, (3S,20S)-3β-Hydroxy-N-(2-methylpropyl)-7-pregnen-20-carboxamid, Lathosteroloxidase Inhibitor

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Über diesen Artikel

Empirische Formel (Hill-System):
C26H43NO2
CAS-Nummer:
Molekulargewicht:
401.63
UNSPSC Code:
12352204
PubChem Substance ID:
MDL number:


biological source

synthetic

assay

≥97.0% (HPLC)

form

crystals and lumps

storage temp.

2-8°C

SMILES string

CC(C)CNC(=O)[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C26H43NO2/c1-16(2)15-27-24(29)17(3)21-8-9-22-20-7-6-18-14-19(28)10-12-25(18,4)23(20)11-13-26(21,22)5/h7,16-19,21-23,28H,6,8-15H2,1-5H3,(H,27,29)/t17-,18-,19-,21+,22-,23-,25-,26+/m0/s1

InChI key

HUMXZYXRXDDZOG-LFZVSNMSSA-N

Biochem/physiol Actions

Lathosterolamide MGI-39 is an inhibitor of lathosterol oxidase which converts 5-α-cholest-7-en-3-β-ol to cholesta-5,7-dien-3β-ol. [1]

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.


pictograms

Exclamation markEnvironment

signalword

Warning

hcodes

pcodes

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Ralf Klingenstein et al.
Journal of neurochemistry, 98(3), 748-759 (2006-06-06)
Prion diseases are invariably fatal, neurodegenerative diseases transmitted by an infectious agent, PrPSc, a pathogenic, conformational isoform of the normal prion protein (PrPC). Heterocyclic compounds such as acridine derivatives like quinacrine abolish prion infectivity in a cell culture model of
Martin Giera et al.
Steroids, 73(3), 299-308 (2008-01-01)
Inhibition of cholesterol biosynthesis offers the opportunity for treatment of cardiovascular diseases. Numerous enzymes are involved in the post-squalene part of this biosynthesis, and selective inhibitors for almost all of the enzymes involved there have been described in literature. The
Ken'ichi Hagiwara et al.
Biological & pharmaceutical bulletin, 30(4), 835-838 (2007-04-06)
In prion diseases, the normal cellular form of prion protein (PrP(C)) is converted into the disease-associated isoforms (PrP(Sc)) which accumulate in the infected tissues. Although the precise mechanism of this conversion remains unsolved, drugs of various categories have been reported